Net Income Summary of UCB SA

UCB SA's latest annual net income in 2023 was 343 Million EUR , down -17.94% from previous year.
UCB SA's latest quarterly net income in 2024 Q2 was 208 Million EUR , down 0.0% from previous quarter.
UCB SA reported an annual net income of 418 Million EUR in 2022, down -60.49% from previous year.
UCB SA reported an annual net income of 1.05 Billion EUR in 2021, up 44.54% from previous year.
UCB SA reported a quarterly net income of 311 Million EUR for 2023 Q2, down 0.0% from previous quarter.
UCB SA reported a quarterly net income of 343 Million EUR for 2023 FY, down -17.94% from previous quarter.

Annual Net Income Chart of UCB SA (2023 - 2002)

Historical Annual Net Income of UCB SA (2023 - 2002)

Year	Net Income	Net Income Growth
2023	343 Million EUR	-17.94%
2022	418 Million EUR	-60.49%
2021	1.05 Billion EUR	44.54%
2020	732 Million EUR	-7.58%
2019	792 Million EUR	-1.0%
2018	800 Million EUR	6.24%
2017	753 Million EUR	44.81%
2016	520 Million EUR	96.97%
2015	264 Million EUR	129.57%
2014	115 Million EUR	40.24%
2013	82 Million EUR	-67.97%
2012	256 Million EUR	8.94%
2011	235 Million EUR	125.96%
2010	104 Million EUR	-79.77%
2009	514 Million EUR	1095.35%
2008	43 Million EUR	-73.29%
2007	161 Million EUR	-56.13%
2006	367 Million EUR	-51.39%
2005	755 Million EUR	107.97%
2004	363.04 Million EUR	6.88%
2003	339.67 Million EUR	2.37%
2002	331.81 Million EUR	0.0%

Year	Net Income	Net Income Growth
2024 Q2	208 Million EUR	0.0%
2023 Q2	311 Million EUR	0.0%
2023 FY	343 Million EUR	-17.94%
2023 Q4	32 Million EUR	0.0%
2022 FY	418 Million EUR	-60.49%
2022 Q2	399 Million EUR	0.0%
2022 Q4	19 Million EUR	0.0%
2021 Q2	571 Million EUR	0.0%
2021 FY	1.05 Billion EUR	44.54%
2021 Q4	487 Million EUR	0.0%
2020 FY	732 Million EUR	-7.58%
2020 Q4	369 Million EUR	0.0%
2020 Q2	363 Million EUR	0.0%
2019 Q4	381 Million EUR	0.0%
2019 FY	792 Million EUR	-1.0%
2019 Q2	411 Million EUR	0.0%
2018 Q2	550 Million EUR	0.0%
2018 FY	800 Million EUR	6.24%
2017 Q4	322 Million EUR	0.0%
2017 FY	753 Million EUR	44.81%
2017 Q2	430 Million EUR	0.0%
2016 FY	520 Million EUR	96.97%
2016 Q2	309 Million EUR	0.0%
2015 FY	264 Million EUR	129.57%
2015 Q4	25 Million EUR	0.0%
2015 Q2	239 Million EUR	0.0%
2014 Q4	29 Million EUR	0.0%
2014 FY	115 Million EUR	40.24%
2014 Q2	86 Million EUR	0.0%
2013 Q4	26 Million EUR	0.0%
2013 Q2	56 Million EUR	0.0%
2013 FY	82 Million EUR	-67.97%
2012 Q3	58.75 Million EUR	0.0%
2012 FY	256 Million EUR	8.94%
2012 Q4	48.75 Million EUR	-17.02%
2012 Q2	58.75 Million EUR	0.0%
2012 Q1	58.75 Million EUR	0.0%
2011 Q1	55.25 Million EUR	0.0%
2011 Q2	55.25 Million EUR	0.0%
2011 Q3	55.25 Million EUR	0.0%
2011 Q4	58.75 Million EUR	6.33%
2011 FY	235 Million EUR	125.96%
2010 Q4	55.25 Million EUR	110.48%
2010 Q2	26.25 Million EUR	0.0%
2010 Q3	26.25 Million EUR	0.0%
2010 Q1	26.25 Million EUR	0.0%
2010 FY	104 Million EUR	-79.77%
2009 Q4	26.25 Million EUR	-79.29%
2009 FY	514 Million EUR	1095.35%
2009 Q2	126.75 Million EUR	0.0%
2009 Q3	126.75 Million EUR	0.0%
2009 Q1	126.75 Million EUR	0.0%
2008 Q3	-3.25 Million EUR	0.0%
2008 FY	43 Million EUR	-73.29%
2008 Q1	-3.25 Million EUR	0.0%
2008 Q2	-3.25 Million EUR	0.0%
2008 Q4	126.75 Million EUR	4000.0%
2007 Q4	-3.25 Million EUR	-108.18%
2007 FY	161 Million EUR	-56.13%
2007 Q3	39.75 Million EUR	0.0%
2007 Q2	39.75 Million EUR	0.0%
2007 Q1	39.75 Million EUR	0.0%
2006 Q3	91.75 Million EUR	0.0%
2006 Q4	39.75 Million EUR	-56.68%
2006 Q2	91.75 Million EUR	0.0%
2006 FY	367 Million EUR	-51.39%
2006 Q1	91.75 Million EUR	0.0%
2005 Q4	91.75 Million EUR	35.93%
2005 FY	755 Million EUR	107.97%
2005 Q2	67.5 Million EUR	0.0%
2005 Q3	67.5 Million EUR	0.0%
2005 Q1	67.5 Million EUR	0.0%
2004 Q2	90.72 Million EUR	0.0%
2004 FY	363.04 Million EUR	6.88%
2004 Q1	90.72 Million EUR	0.0%
2004 Q3	90.72 Million EUR	0.0%
2004 Q4	67.5 Million EUR	-25.6%
2003 Q4	90.72 Million EUR	7.04%
2003 Q3	84.75 Million EUR	0.0%
2003 Q1	84.75 Million EUR	0.0%
2003 Q2	84.75 Million EUR	0.0%
2003 FY	339.67 Million EUR	2.37%
2002 Q3	82.51 Million EUR	0.0%
2002 Q2	82.51 Million EUR	0.0%
2002 Q1	82.51 Million EUR	0.0%
2002 FY	331.81 Million EUR	0.0%
2002 Q4	84.75 Million EUR	2.71%
2001 Q4	82.51 Million EUR	0.0%

Peer Net Income Comparison of UCB SA

Name	Net Income	Net Income Difference
Nicox S.A.	-20.88 Million EUR	1742.642%
European Medical Solutions	-709 Thousand EUR	48477.997%
FERMENTALG	-14.14 Million EUR	2524.371%
argenx SE	-272.91 Million EUR	225.68%
BioSenic S.A.	-28.77 Million EUR	1291.883%
Celyad Oncology SA	-8.44 Million EUR	4160.133%
Hyloris Pharmaceuticals SA	-15.38 Million EUR	2330.169%
Onward Medical N.V.	-36.18 Million EUR	1048.011%
Oxurion NV	-18.96 Million EUR	1908.213%
PHAXIAM Therapeutics S.A.	-23.48 Million EUR	1560.32%
Financière de Tubize SA	88.15 Million EUR	-289.104%

Global Stocks Search

UCB SA (UCB.BR)

Net Income Summary of UCB SA

Annual Net Income Chart of UCB SA (2023 - 2002)

Historical Annual Net Income of UCB SA (2023 - 2002)

Peer Net Income Comparison of UCB SA